Gilead inks $90m deal with Verily to create “molecular map” of inflammatory disease

Gilead Sciences (NSDQ:GILD) is reportedly slated to pay Alphabet’s Verily Life Sciences $90 million over three years to analyze cells from patients with rheumatoid arthritis, inflammatory bowel disease and lupus-related diseases.

By probing immune cells from patients involved in Gilead’s clinical trials, the companies hope to glean a better understanding of the immunological signatures of RA, IBD and lupus-related diseases. It’s the first large-scale use of Verily’s Immunoscape platform, which combines immunogenomic phenotyping and computational analysis to profile the molecular characteristics of inflammatory diseases.

Get the full story at our sister site, Drug Delivery Business News.

The post Gilead inks $90m deal with Verily to create “molecular map” of inflammatory disease appeared first on MassDevice.

from MassDevice https://ift.tt/2jjjBLG